Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
Grifols Sa Barcelona Sponsored ADR (AMEX: GIKLY) Delayed: 5.75 --0 (-0%)
Previous Close $5.75    52 Week High $24.05 
Open $5.75    52 Week Low $9.74 
Day High $5.75    P/E N/A 
Day Low $5.75    EPS $0.00 
Volume 18,519,779       

EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) Delayed: 10.34 --0 (-0%)
Previous Close $10.34    52 Week High $21.75 
Open $10.34    52 Week Low $6.41 
Day High $10.34    P/E N/A 
Day Low $10.34    EPS $0.00 
Volume 17       

GRIFOLS SP ADR-B (NASDAQ: GRFS) Delayed: 7.31 -0.09 (1.22%)
Previous Close $7.40    52 Week High $35.35 
Open $7.37    52 Week Low $14.07 
Day High $7.41    P/E N/A 
Day Low $7.29    EPS $0.00 
Volume 367,746       

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Delayed: 46.64 +0.79 (1.72%)
Previous Close $45.85    52 Week High $4.38 
Open $45.54    52 Week Low $1.88 
Day High $46.99    P/E N/A 
Day Low $45.24    EPS $-1.12 
Volume 939,564